Clinical Trials Browser

Phase 2 × Carcinoma, Non-Small-Cell Lung × pembrolizumab × Clear all

NCT02818920 2026-03-17

TOP 1501

Phase 2 Completed

35 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT03412877 2026-03-17

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

Phase 2 Recruiting

BreastEndocrineGynecologicNETPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Multiple Myeloma, Ovarian Neoplasms, Urogenital Neoplasms, Neuroendocrine Tumors

NCT03485209 2026-03-16

innovaTV 207

Phase 2 Active not recruiting

GastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT04609566 2026-03-16

Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors

Phase 2 Completed

DermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT07452224 2026-03-12

ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07017829 2026-03-11

GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04736173 2026-03-09

ARC-10

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05669846 2026-03-09

Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT04253964 2026-03-06

Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06731907 2026-02-18

MK-3475-01G

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06731270 2026-02-12

Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05186974 2026-02-11

EVOKE-02

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05775289 2026-02-11

A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer

Phase 2 Active not recruiting

182 enrolled 35 charts

Carcinoma, Non-Small-Cell Lung

NCT07360743 2026-02-10

META-1

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT05816252 2026-01-27

MK-2870-003

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04166487 2026-01-21

Plasma-Adapted First-Line Pembro In NSCLC

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03228667 2026-01-14

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

Phase 2 Active not recruiting

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT05565378 2026-01-08

A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05141357 2025-12-24

HBI-8000

Phase 2 Terminated

5 enrolled 8 charts

Carcinoma, Non-Small-Cell Lung

NCT03634241 2025-12-22

Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung Study

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05570825 2025-12-04

SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04165083 2025-11-26

MK-3475-01B

Phase 2 Completed

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT05256381 2025-11-17

A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors

Phase 2 Terminated

166 enrolled 43 charts

GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Ovarian Neoplasms, Colorectal Neoplasms

NCT07223424 2025-11-10

PSI-Immune

Phase 2 Recruiting

DermatologicGastrointestinalGenitourinaryGynecologicThoracic

Adenocarcinoma Of Esophagus, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Colitis, Ulcerative, Colonic Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma

NCT04225117 2025-11-03

A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

Phase 2 Active not recruiting

BreastGastrointestinalHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Triple Negative Breast Neoplasms

NCT06558799 2025-10-28

LUNAR-4

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT03049618 2025-10-22

Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475

Phase 2 Completed

42 enrolled 40 charts

Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung

NCT05846646 2025-10-20

Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC

Phase 2 Terminated

6 enrolled 7 charts

GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell

NCT07207395 2025-10-06

A Study of Orally Administered JBI-802 Alone or in Combination With Pembrolizumab for Patients With Non-small Cell Lung Cancer With an STK11 Mutation.

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04914897 2025-10-02

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)

Phase 2 Terminated

106 enrolled 21 charts

Other solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung

NCT06822543 2025-09-29

TROPICAL-1

Phase 2 Recruiting

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03184571 2025-09-25

Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Phase 2 Completed

99 enrolled 20 charts

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

NCT06364917 2025-09-03

DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT03322540 2025-08-22

Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)

Phase 2 Completed

154 enrolled 14 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05609578 2025-08-17

Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02546986 2025-08-08

Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer

Phase 2 Completed

100 enrolled 27 charts

Carcinoma, Non-Small-Cell Lung

NCT04581824 2025-08-08

Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)

Phase 2 Terminated

243 enrolled 21 charts

Carcinoma, Non-Small-Cell Lung

NCT02681549 2025-08-07

Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)

Phase 2 Completed

41 enrolled 20 charts

CNSDermatologicThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT05617313 2025-07-30

Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer

Phase 2 Terminated

Carcinoma, Non-Small-Cell Lung

NCT05691829 2025-07-29

IRRADIATE-Lung

Phase 2 Terminated

19 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT05894889 2025-07-23

Pembrolizumab and Chemotherapy Neoadjuvant/Adjuvant of NSCLC

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06902272 2025-07-22

DNA-PREDICT

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06951399 2025-07-22

Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT04120454 2025-07-11

Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Cancer

Phase 2 Completed

6 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04165096 2025-06-25

MK-3475-01C

Phase 2 Completed

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT05589818 2025-06-25

Pembrolizumab for Advanced NSCLC and PS 2-3

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT03645928 2025-06-19

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

Phase 2 Recruiting

DermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT02705820 2025-06-17

SWIPE

Phase 2 Completed

48 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT04533451 2025-06-13

Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer

Phase 2 Active not recruiting

101 enrolled 21 charts

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03242915 2025-05-30

Pembrolizumab Plus Chemotherapy in NSCLC With Targetable Genetic Alterations After Progression on Targeted Agents

Phase 2 Completed

33 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung